RT Journal Article
SR Electronic
T1 Serology confirms SARS-CoV-2 infection in PCR-negative children presenting with Paediatric Inflammatory Multi-System Syndrome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.05.20123117
DO 10.1101/2020.06.05.20123117
A1 Marisol Perez-Toledo
A1 Sian E. Faustini
A1 Sian E. Jossi
A1 Adrian M. Shields
A1 Hari Krishnan Kanthimathinathan
A1 Joel D. Allen
A1 Yasunori Watanabe
A1 Margaret Goodall
A1 David C. Wraith
A1 Tonny V. Veenith
A1 Mark T. Drayson
A1 Deepthi Jyothish
A1 Eslam Al-Abadi
A1 Ashish Chikermane
A1 Steven B. Welch
A1 Kavitha Masilamani
A1 Scott Hackett
A1 Max Crispin
A1 Barnaby R Scholefield
A1 Adam F. Cunningham
A1 Alex G. Richter
YR 2020
UL http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123117.abstract
AB Background During the COVID-19 outbreak, reports have surfaced of children who present with features of a multisystem inflammatory syndrome with overlapping features of Kawasaki disease and toxic shock syndrome – Paediatric Inflammatory Multisystem Syndrome-temporally associated with SARS-CoV-2 pandemic (PIMS-TS). Initial reports find that many of the children are PCR-negative for SARS-CoV-2, so it is difficult to confirm whether this syndrome is a late complication of viral infection in an age group largely spared the worst consequences of this infection, or if this syndrome reflects enhanced surveillance.Methods Children hospitalised for symptoms consistent with PIMS-TS between 28 April and 8 May 2020, and who were PCR-negative for SARS-CoV-2, were tested for antibodies to viral spike glycoprotein using an ELISA test.Results Eight patients (age range 7–14 years, 63% male) fulfilled case-definition for PIMS-TS during the study period. Six of the eight patients required admission to intensive care. All patients exhibited significant IgG and IgA responses to viral spike glycoprotein. Further assessment showed that the IgG isotypes detected in children with PIMS-TS were of the IgGl and lgG3 subclasses, a distribution similar to that observed in samples from hospitalised adult COVID-19 patients. In contrast, lgG2 and lgG4 were not detected in children or adults. IgM was not detected in children, which contrasts with adult hospitalised adult COVID-19 patients of whom all had positive IgM responses.Conclusions Strong IgG antibody responses can be detected in PCR-negative children with PIMS-TS. The low detection rate of IgM in these patients is consistent with infection having occurred weeks previously and that the syndrome onset occurs well after the control of SARS-CoV-2 viral load. This implies that the disease is largely immune-mediated. Lastly, this indicates that serology can be an appropriate diagnostic tool in select patient groups.Competing Interest StatementAuthors declare no competing interests except for Dr. Mark Drayson who owns shares in Abingdon Health.Funding StatementAFC is grateful for funding from The Medical Research Council and The Institute for Global Innovation, The University of Birmingham for funding. This study was supported by the UK National Institute for Health Research, Birmingham Biomedical Research Centres Funding scheme. Dr Barnaby Scholefield is funded by the NIHR Clinician Scientist fellowship programme. The work in Prof. Max Crispin's laboratory was funded by the International AIDS Vaccine Initiative, Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (OPP1084519 and OPP1115782), the Scripps Consortium for HIV Vaccine Development (CHAVD) (AI144462), and the University of Southampton Coronavirus Response Fund which has over 1000 donors from around the world.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical approval for this work and the use of these samples was provided by the awarding bodies of the University of Birmingham Research Ethics Committee, the South Birmingham Research Ethics Committee and the National Research Ethics Service Committee West Midlands. All approvals are overseen by the United Kingdom National Health Service and this is therefore a NHS Health Research Authority approved study. All patients and/or their parents/legal guardians provided signed informed consent to inclusion of de-identified data in this report.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.